-The Hindu In the year 2011, 438 people died due to Serious Adverse Events (SAEs) during medicine trials in India, but pharmaceutical companies provided financial compensation in only 16 such cases. The total amount paid in compensation in all the 16 cases adds up to Rs. 34.88 lakh, with the highest amount being Rs. 5 lakh, and the lowest being Rs. 50,000. This makes 2011 only the second year, for which data are...

-The Indian Express At a time when the government is struggling to get past objections from its coalition partners to attract investment in certain sectors such as retail, aviation and pensions fund management, a grim internecine ministerial battle has applied the brakes on foreign direct investment flow into one of the more attractive and lucrative sectors — pharmaceuticals. Clearances for over Rs 1,000 crore FDI in this sector, the second largest in...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...

-The Indian Express India may not be a testing hub for Big pharma. But informed consent must be non-negotiable Figures released by the World Health Organisation, which show that 10 Indian subjects of clinical field trials die every week, have rekindled concerns that this country has become a testing hub for Big pharma. Ironically, the same figures deflate this persistent fear, revealing that only 1.5 per cent of global trials have been...